SCHEMBL20203604

SCHEMBL20203604

CC(C)c1ccc(N2CCN(CCS(C)(=O)=O)CCC2=O)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.36
HRH3 Q9Y5N1 2/20 0.33
ALK Q9UM73 1/20 0.33
SMO Q99835 1/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
SYK P43405 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
DRD3 P35462 1/20 0.32
KCNH2 Q12809 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
TLR9 Q9NR96 2/20 0.31
TLR8 Q9NR97 2/20 0.31
TLR7 Q9NYK1 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203463 0.86 ALDH1A1 (0.38) HRH3PRMT5WDR77DRD3KCNH2
SCHEMBL20203460 0.80 HPGD (0.39) AKR1C3HRH3DRD3KCNH2NPC1
SCHEMBL21509722 0.76 AKR1C3 (0.49) AKR1C3HRH3NPC1
SCHEMBL14525387 0.75 AKR1C3 (0.48) AKR1C3HRH3
SCHEMBL21414431 0.75 NPC1 (0.35) AKR1C3HRH3NPC1RAB9AMEN1
SCHEMBL10256825 0.74 SLC6A2 (0.42) AKR1C3HRH3PRMT5WDR77DRD3
SCHEMBL22877029 0.73 DRD3 (0.32) AKR1C3HRH3DRD3KCNH2NPC1
SCHEMBL20203473 0.72 HTR6 (0.40) AKR1C3HRH3
SCHEMBL20203458 0.71 HTR6 (0.35)
SCHEMBL20037546 0.70 DRD3 (0.45) DRD3KCNH2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 AKR1C3 2241/4885HRH3 2223/4885ALK 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.